White Paper

Accelerating Biopharmaceutical Development From DNA To Drug

Source: Sartorius

By Floris De Smet, Juan Pablo Acosta-Martinez, Nick Hutchinson, Christel Fenge and Miriam Monge


The pipeline of biopharmaceutical drugs is rich and becoming increasingly diverse. Many new biologic modalities are being developed as established therapeutic classes move through their lifecycle. Wide arrays of different types of molecules are expected to coexist within product portfolios and manufacturing networks. It is clear that this will have a significant impact on manufacturing facilities. Strategies need to be developed to prepare facilities for these challenges.

Single-use technologies have received considerable attention in recent years as a great platform to tackle the multi-modality manufacturing conundrum. These technologies can be used to reduce time to clinic, delay investment decisions and allow a high degree of operational flexibility. Over the last decade, single-use solutions for virtually every bioprocess unit operation have been developed and considerable investments have been made by the industry into optimizing the quality and supply chain that underpin this technology (Cappia et al., 2014).

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online